NCT00290693View on ClinicalTrials.gov

Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

August 31, 2008

Study Completion Date

June 30, 2010

Conditions
Pancreatic Cancer
Interventions
DRUG

Capecitabine

Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle

DRUG

Docetaxel

30 mg/m2, IV, days 1 and 8 every 3 weeks

Trial Locations (3)

32224

Mayo Clinic - Jacksonville, Jacksonville

33136

University of Miami, Miami

33140

Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center, Miami Beach

All Listed Sponsors
lead

University of Miami

OTHER

NCT00290693 - Capecitabine and Docetaxel in Treating Patients With Recurrent or Progressive Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter